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Abstract	
	
Background:	Prognostic	predictive	models	are	used	in	the	delivery	of	primary	care	to	estimate	a	
patient’s	risk	of	future	disease	development.	Electronic	medical	record	(EMR)	data	can	be	used	
for	the	construction	of	these	models.	Objectives:	To	provide	a	framework	for	those	seeking	to	
develop	prognostic	predictive	models	using	EMR	data,	and	to	illustrate	these	steps	using	
osteoarthritis	risk	estimation	as	an	example.	
Methods	(FRAMR-EMR):	The	FRAmework	for	Modelling	Risk	from	EMR	data	(FRAMR-EMR)	was	
created,	which	outlines	step-by-step	guidance	for	the	construction	of	a	prognostic	predictive	
model	using	EMR	data.	Our	framework	is	composed	of	four	main	steps:	Scoping	and	
Background	Search;	Data	Preparation;	Cohort	Construction;	and	Model	Building	and	Evaluation.	
Throughout	these	steps,	several	potential	pitfalls	specific	to	using	EMR	data	for	predictive	
purposes	are	described	and	methods	for	addressing	them	are	suggested.	
Results	(Case	Study):	We	used	the	DELPHI	(DELiver	Primary	Healthcare	Information)	database	
to	develop	a	prognostic	predictive	model	for	estimation	of	osteoarthritis	risk.	We	constructed	a	
retrospective	cohort	of	28,447	eligible	primary	care	patients.	Patients	were	included	in	the	
cohort	if	they	had	an	encounter	with	their	primary	care	practitioner	between	1	January	2008	
and	31	December	2009;	additionally,	patients	were	required	to	have	an	encounter	following	
the	follow-up	window	to	ensure	patients	were	not	lost	to	follow-up.	Patients	were	excluded	if	
they	had	a	diagnosis	of	osteoarthritis	prior	to	baseline.	Construction	of	a	prognostic	predictive	
model	following	FRAMR-EMR	yielded	a	predictive	model	capable	of	estimating	5-year	risk	of	
osteoarthritis	diagnosis.	Logistic	regression	was	used	to	predict	osteoarthritis	based	on	age,	sex,	
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BMI,	previous	leg	injury,	and	osteoporosis.	Internal	validation	of	the	model’s	performance	
demonstrated	good	discrimination	and	moderate	calibration.	
Conclusions:	This	study	provides	guidance	to	those	interested	in	developing	prognostic	
predictive	models	based	on	EMR	data.	The	production	of	high	quality	prognostic	predictive	
models	allows	for	practitioner	communication	of	accurately	estimated	risks	of	developing	
future	disease	among	primary	care	patients.	This	allows	practitioners	and	patients	to	create	
unique	plans	for	addressing	patient	personal	risk	factors.	
	
Keywords:	FRAMR-EMR,	prognostic	predictive	modelling,	osteoarthritis,	health	informatics,	
electronic	medical	records,	DELPHI,	risk	prediction,	primary	care.	
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Introduction	
	
Primary	care	is	an	ideal	setting	for	the	implementation	of	interventions	to	evaluate	and	reduce	
the	risk	of	developing	chronic	disease	[1,2].	Furthermore,	the	current	level	of	electronic	medical	
records	(EMR)	use	in	primary	care	[3–6]	has	sparked	interest	in	using	EMR-derived	databases	
for	research	purposes	[7],	including	risk	modelling.	Hence,	the	primary	care	setting	presents	a	
unique	opportunity	for	developing	risk	models	that	are	tailored	to	the	very	population	who	can	
make	effective	use	of	them.	
	
Predictive	models	can	be	broken	down	into	those	that	estimate	the	risk	of	disease	presence	
(diagnostic)	and	those	that	estimate	the	risk	of	future	disease	development	(prognostic)	[8,9].	
Prognostic	predictive	models	estimate	a	patient’s	risk	of	future	disease	development	based	on	
that	patient’s	predictors	of	disease	[8,9].	Predictors	may	include	patient	demographics	(such	as	
age	and	sex),	family	history,	lifestyle	factors	(such	as	smoking	status	or	physical	activity	level),	
laboratory	results,	prior	medical	conditions,	or	genetic	markers	[10].	The	estimates	produced	by	
a	predictive	model	can	be	used	in	the	patient	care	decision-making	process	of	the	primary	care	
practitioner	by	informing	patients	and	practitioners	of	future	risk	of	disease	[11,12].	Predictive	
models	have	been	used	to	predict	the	development	of	many	chronic	diseases	in	patients	[13–
15],	including	osteoarthritis	[16].	They	have	been	effective	in	improving	patients’	risk	
perception	and	knowledge	of	risk	[17]	and	in	modifying	primary	care	practitioner	behaviour,	
including	changes	in	practitioner	prescribing	practices	[18].		
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Primary	care	EMR	databases	have	several	advantages	over	other	data	sources	for	use	in	
predictive	risk	modelling:		
• EMR	data	are	often	more	abundant	and	less	expensive	to	collect	[19–21]	
• They	often	represent	a	broader	sample	of	the	population	compared	to	cohort	studies	
that	depend	on	volunteer	participation	[20]	
• They	often	have	longitudinal	data	spanning	months	or	years	
• When	EMR	data	are	used	to	build	risk	estimation	tools,	these	tools	can	be	more	easily	
utilized	in	existing	EMR	software	because	they	use	risk	indicators	that	are	already	
present	in	EMR	data	[20]	–	an	attribute	that	is	greatly	desired	by	primary	care	
practitioners	[22]	
However,	EMR	data	come	with	a	distinct	set	of	challenges:		
• EMR	data	are	more	prone	to	have	missingness	compared	to	data	collected	specifically	
for	research	purposes	[20,23,24]		
• EMR	data	often	lack	standardization	in	terms	of	what	data	are	collected,	how	they	are	
collected,	and	how	they	are	stored	[20,21]		
	
The	TRIPOD	(Transparent	Reporting	of	a	multivariable	prediction	model	for	Individual	Prognosis	
Or	Diagnosis)	Statement	[25]	provides	a	comprehensive	description	of	the	methods	required	
for	developing	predictive	models;	however,	as	it	is	a	reporting	guideline,	the	TRIPOD	statement	
was	not	designed	to	guide	predictive	model	development.	To	complement	the	TRIPOD	
statement,	we	present	FRAMR-EMR,	the	FRAmework	for	Modelling	Risk	from	EMR	data,	which	
is	intended	to	serve	as	a	guideline	for	researchers	who	wish	to	develop	prognostic	predictive	
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models,	with	a	specific	focus	on	the	use	of	EMR	data.	We	then	present	a	case	study	
demonstrating	how	we	applied	FRAMR-EMR	to	EMR	data	to	develop	a	prognostic	predictive	
model	for	osteoarthritis.		
	
Methods	(FRAMR-EMR)	
	
We	developed	the	following	framework	based	on	the	methods	suggested	by	Moons	et	al.	[25],	
Steyerberg	[26],	Lee	et	al.	[10],	and	Hendriksen	et	al.	[8].	Our	framework	extends	this	research,	
as	we	have	developed	our	framework	specifically	for	use	with	EMR	data	and	have	highlighted	
several	concerns	that	are	unique	to	EMR	data.	We	intend	for	this	framework	to	be	used	by	
researchers	with	a	background	in	statistics	but	with	possibly	limited	experience	in	predictive	
modelling	who	are	interested	in	predicting	disease	outcomes.	FRAMR-EMR	comprises	four	main	
steps:	Scoping	and	Background	Search,	Data	Preparation,	Cohort	Construction,	and	Model	
Building	and	Evaluation.	See	Appendix	1	for	a	flow	diagram	of	the	framework.	
	
1.	Scoping	and	Background	Search:	
	
When	developing	a	prognostic	predictive	model,	researchers	typically	have	a	target	population	
and	a	disease	or	health	outcome	in	mind,	which	define	the	scope	of	the	project.	Given	this	
scope,	the	next	important	step	is	a	review	of	the	literature	to	identify	relevant	risk	indicators.	
We	use	the	term	risk	indicator	to	mean	any	patient	attribute	that	helps	estimate	risk.	Risk	
indicators	can	be	broken	into:	risk	factors,	indicators	that	have	strong	evidence	for	a	causal	
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effect;	and	risk	markers,	indicators	that	are	associated	but	with	unproven	causality	[27].	
Identifying	risk	indicators	a	priori	based	on	scientific	and	clinical	knowledge	helps	avoid	the	
discovery	of	spurious	associations	[8].	Having	identified	the	potentially	relevant	risk	indicators	
for	the	disease	or	outcome	of	interest,	a	collection	of	risk	factors	and	markers	should	be	
identified	as	candidates	for	inclusion	in	the	final	model	using	the	principles	of	analytic	
epidemiology	[28].	
	
With	these	risk	indicators	in	hand,	the	next	important	decision	is	the	selection	of	a	data	source.	
Our	focus	is	the	use	of	EMR	databases	as	a	data	source.	Many	jurisdictions	are	developing	
aggregated	primary	care	databases	[29–32]	that	are	available	to	primary	care	researchers.	
Different	databases	invariably	contain	different	information,	and	may	have	had	cleaning	steps	
applied	to	address	issues	such	as	missing	or	implausible	data.	Some	more	well-developed	
databases	may	have	been	validated	using	methods	such	as	chart	review	to	ensure	correctness	
of	the	data.	It	is	important	to	understand	what	cleaning	steps	have	been	applied,	the	
provenance	of	the	data,	and	the	characteristics	of	the	population	contained	in	the	data	source.	
The	more	closely	the	distribution	of	patients	in	the	data	source	matches	the	population	to	
which	the	resulting	risk	model	will	eventually	be	applied,	the	better	the	predictive	performance	
will	be.	In	the	case	of	using	primary	care	EMR	data,	the	risk	model	may	not	be	directly	
applicable	to	the	general	population	as	the	data	used	to	derive	the	model	are	not	
representative	of	the	general	population.	However,	they	are	representative	of	the	primary	care	
population,	a	common	setting	for	risk	estimation;	thus,	risk	models	derived	from	primary	care	
data	can	be	confidently	applied	to	primary	care	populations.		
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2.	Data	Preparation	and	Definition:	
	
An	EMR	is	a	rich	source	of	information	regarding	a	patient’s	medical	conditions,	health	
concerns,	symptoms,	laboratory	results,	physiologic	measures,	and	medication	history.	From	
this	record,	we	can	extract	data	about	a	patient’s	disease	and	risk	indicator	status.	A	disease	or	
risk	indicator	might	be	extracted	as	a	binary	variable	(e.g.,	disease	present	or	not	present)	or	as	
a	continuous	value	(e.g.,	BMI	of	24)	depending	on	how	the	pertinent	data	are	stored	in	the	
database	and	on	modelling	choices.	We	strongly	recommend	developing	precise	disease	case	
and	risk	indicator	definitions	that	describe	exactly	how	the	disease	or	indicator	status	is	derived	
from	the	available	data.	For	simpler	definitions,	a	set	of	decision	rules	may	suffice	[33].	When	
constructing	these	case	definitions,	it	is	best	to	draw	on	both	written	documentation	of	the	
database	(e.g.	a	data	dictionary	[34])	as	well	as	consultation	with	EMR	users.	One	common	way	
of	identifying	diseases	is	to	examine	the	diagnosis	codes	within	the	billing	records	and	problem	
list	of	the	EMR.	Consultation	with	EMR	users	is	an	important	step	to	ensure	that	the	extraction	
process	makes	valid	assumptions	about	how	disease	and	risk	factor	information	are	coded	and	
stored	within	the	EMR	in	practice.	Ideally,	the	definition	should	be	validated	against	a	gold	
standard	(e.g.	chart	review)	where	possible;	however,	given	the	evolving	nature	of	this	field,	it	
is	often	not	feasible	to	have	a	set	of	validated	risk	indicator	definitions.	Using	EMR	user	
consultation	to	develop	the	definitions	helps	ensure	their	validity	when	chart	review	is	not	
possible.	We	strongly	recommend	validation	of	the	disease	outcome	under	study	to	avoid	
systematic	over-	or	under-estimation	of	risk.	
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As	the	process	of	understanding	the	data,	consulting	with	EMR-users,	and	developing	
definitions	proceeds,	it	is	useful	to	consider	the	dimensions	of	data	quality	of	electronic	health	
records	(EHR)	described	by	Weiskopf	and	Weng	[35]:	completeness,	correctness,	concordance,	
plausibility,	and	currency.	EHRs	and	EMRs	are	very	similar,	thus	these	concepts	pertaining	to	
EHRs	can	easily	be	applied	to	EMRs.	These	concepts	are	defined	as	follows:	“(1)	Completeness:	
Is	a	truth	about	a	patient	present	in	the	EHR?” (2)	“Correctness:	Is	an	element	that	is	present	in	
the	EHR	true?”	(3)	“Concordance:	is	there	agreement	between	elements	in	the	EHR,	or	
between	the	EHR	and	another	data	source?”	(4)	“Plausibility:	does	an	element	in	the	EHR	make	
sense	in	light	of	other	knowledge	about	what	the	element	is	measuring?”	(5)	“Currency:	is	an	
element	in	the	EHR	a	relevant	representation	of	the	patient	state	at	a	given	point	in	time?”.	
Assessing	each	of	these	dimensions	as	the	project	proceeds	will	strengthen	the	validity	of	the	
end	result,	and	we	refer	the	reader	to	the	work	by	Weiskopf	and	Weng	for	a	more	detailed	
account.	However,	we	note	several	issues	specifically	pertinent	to	EMR	data	under	the	
dimensions	of	Completeness,	Correctness	(with	Concordance	and	Plausibility	as	subordinate	
issues),	and	Currency.		
	
Completeness:	The	role	of	EMRs	is	to	facilitate	the	collection	and	storage	of	data	that	support	
the	delivery	of	patient	care	[24,36],	rather	than	research.	Hence,	data	that	are	relevant	to	risk	
modelling	but	unimportant	from	a	clinical	care	standpoint	may	be	missing.	In	practice,	dealing	
with	partially	missing	data	is	a	common	problem;	hence	we	discuss	some	specific	mitigating	
strategies	here.	Where	no	data	can	be	found	regarding	a	particular	risk	indicator,	it	may	be	
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possible	to	link	with	external	data	sources	to	extract	this	information.	(For	example,	risk	
indicators	missing	from	a	primary	care	EMR	may	be	present	in	a	hospital	EMR,	and	could	be	
linked	using	a	unique	patient	ID.)	If	risk	indicator	data	are	present	for	some	patients	but	not	
others,	several	different	approaches	may	be	appropriate.	In	the	case	of	missing	diagnoses	(e.g.	
some	patients	have	a	diagnosis	of	asthma	while	most	do	not),	it	may	be	reasonable	to	assume	
that	a	missing	diagnosis	indicates	that	no	disease	is	present.	The	validity	of	this	assumption	is	
dependent	upon	the	disease	or	condition,	and	on	the	associated	diagnostic	and	coding	
practices	of	primary	care	practitioners	who	populate	the	database;	this	once	again	underscores	
the	need	for	effective	user	consultation.	In	the	case	of	missing	measurement	data,	such	as	
physiologic	measures	or	laboratory	results,	imputation	methods	may	be	appropriate	for	filling	
in	these	missing	values	[37].	However,	great	care	must	be	taken	as	very	often	measurements	
will	be	missing	because	the	practitioner	has	no	reason	to	believe	a	measurement	result	would	
be	abnormal	and	hence	no	reason	to	order	the	test;	in	that	case,	a	“missing	as	normal”	
assumption	may	be	appropriate	[38].	Besides	considering	the	reasons	why	data	are	missing,	
one	must	also	consider	whether	there	are	sufficient	original	data	for	the	results	of	multiple	
imputation	to	be	reliable.	We	propose	a	simple	simulation-based	approach	to	assess	the	impact	
of	imputation.	Start	by	considering	only	the	complete	cases.	If	these	are	many,	proceed	by	
artificially	eliminating	data	in	a	random	fashion	(but	possibly	depending	on	other	data	items)	
from	the	risk	factor	of	interest	to	varying	degrees.	Repeat	this	procedure	to	create	multiple	
datasets,	each	with	a	greater	degree	of	missingness.	For	each	of	these	artificially	created	
datasets,	impute	the	missing	data	using	multiple	imputation,	and	assess	the	ability	of	the	
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imputation	method	to	correctly	fill	in	the	missing	data.	This	process	will	aid	in	determining	to	
what	extent	data	must	be	complete	to	provide	reliable	information	for	predictive	purposes.	
	
Correctness:	Determining	the	correctness	of	our	data	would	require	a	“gold	standard”	(a	data	
source	containing	the	true	values	of	all	data	within	the	EMR);	however,	usually	no	such	“gold	
standard”	exists	[39].	An	examination	of	data	concordance	(whether	or	not	data	agree	over	
time	and	across	data	sources)	and	plausibility	(whether	the	data	are	physiologically	and	
reasonably	possible)	is	a	useful	way	to	identify	incorrect	data.	It	is	often	the	case	that	multiple	
data	elements	in	an	EMR	database	provide	information	about	the	same	risk	indicator,	because	
it	is	common	for	the	same	information	to	be	recorded	by	the	primary	care	practitioner	in	
multiple	areas	of	the	EMR	[24].	Where	these	data	elements	referring	to	the	same	risk	factor	
disagree,	these	disagreements	must	be	resolved.	Determining	which	(if	any)	of	these	values	is	
correct	requires	careful	consideration	aided	by	clinical	insight.	For	physiologic	values	with	
known	plausible	ranges,	it	may	be	possible	to	identify	and	eliminate	data	that	do	not	fall	within	
these	ranges	[35].	This	is	a	key	part	of	data	cleaning	and	should	be	applied	to	all	such	variables,	
because	values	outside	plausible	ranges	are	not	only	incorrect,	but	may	also	be	outliers	that	
influence	undue	(and	incorrect)	influence	on	estimated	risk	models.	In	this	case,	it	may	be	
better	to	delete	the	values	and	use	an	imputation	method	to	compensate.	
	
Currency:	EMRs	typically	contain	data	reaching	back	to	when	the	systems	were	first	installed,	
and	some	contain	records	that	have	been	scanned	or	manually	entered	from	previous	paper	
records.	We	stress	the	importance	of	ensuring	that	data	are	reasonably	current	for	use,	as	
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there	may	be	cohort	effects	on	risk	that	could	be	mitigated	by	using	up-to-date	data.	Criteria	
for	determining	whether	the	data	are	sufficiently	current	will	vary	depending	on	the	disease	
and	risk	factors.	
	
3.	Cohort	Construction	
	
Our	goal	is	to	accurately	model	risk	of	developing	the	outcome	of	interest	over	a	pre-specified	
time	period.	As	patient	data	in	the	EMR	are	often	organized	into	“encounters”	or	“visits”	that	
record	time-stamped	data	produced	during	an	encounter	with	a	practitioner,	we	suggest	using	
these	data	to	construct	a	retrospective	cohort.	Each	patient	will	have	a	unique	start-date	within	
a	given	timeframe,	at	which	the	risk	indicator	and	outcome	definitions	developed	in	Step	2	of	
our	framework	should	be	applied	to	determine	their	values.	Eliminate	patients	who	already	
have	the	outcome	of	interest	at	this	point	as	these	patients	are	not	susceptible	to	the	disease.	
To	determine	whether	the	patient	developed	the	outcome	of	interest	during	the	specified	time	
period,	we	again	apply	the	outcome	definition	to	all	encounter	data	recorded	in	the	interval.	If	
we	find	that	the	disease	is	present	anywhere	in	the	interval,	we	record	the	event	and	also	
possibly	the	time	of	the	event,	identifying	that	individual	as	a	case.	Individuals	for	whom	we	do	
not	detect	the	event	become	non-cases.	When	working	with	EMR	data,	it	is	important	to	note	
that	there	is	no	way	to	know	whether	or	not	patients	have	been	censored;	that	is,	we	cannot	
know	for	certain	the	status	of	the	patient	without	record	of	an	encounter	as	the	patient	may	
not	have	sought	help	for	the	disease	or	may	have	sought	medical	attention	elsewhere.	We	
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suggest	requiring	an	individual	to	have	at	least	one	observed	encounter	after	the	period	of	
interest	to	confirm	them	as	a	non-case.		
	
4.	Model	Building	and	Evaluation:	
	
Retrospective	cohorts	constructed	from	EMRs	as	we	have	described	above	can	be	analyzed	
using	many	of	the	same	techniques	as	other	cohorts;	however,	given	their	typically	much	larger	
sample	size,	we	make	the	following	specific	recommendations	for	building	and	evaluating	
models:		
• Partition	the	cohort	into	training,	development,	and	validation	sets	[40].	The	training	set	
will	be	used	when	building	the	predictive	models.	The	development	set	will	be	used	to	
assess	the	performance	of	each	potential	model	and	select	the	optimal	model.	The	
validation	set—sometimes	called	the	“test	set”	in	machine	learning	literature—will	be	
used	to	evaluate	the	performance	of	the	final	model.	There	is	concern	surrounding	how	
large	the	development	and	validation	sets	should	be.	One	method	of	determining	the	
minimum	sufficient	size	considers	the	c-statistic.	In	keeping	with	the	TRIPOD	guidelines	
[25],	the	c-statistic	is	a	measure	that	is	reported	for	the	purposes	of	model	validation.	
The	c-statistic	measures	discrimination,	the	ability	of	the	model	to	assign	greater	risk	to	
a	patient	who	will	develop	disease	compared	to	one	who	will	not,	given	their	risk	
factors.	A	c-statistic	of	0.5	means	the	model	is	no	better	than	randomly	assigning	
greater	risk;	any	value	greater	than	0.5	means	the	model	is	performing	better	than	
random.	The	minimum	partition	size	for	the	development	and	test	sets	to	detect	a	
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significant	difference	from	a	c-statistic	of	0.5	can	be	determined	given	a	significance	
level,	power,	and	kappa	value	(the	ratio	of	controls	to	cases)	[41].	For	example,	to	
detect	a	difference	of	0.05	from	random	at	a	5%	significance	level,	80%	power,	and	
kappa	value	of	10	(corresponding	to	ten	times	the	number	of	controls	as	cases),	274	
cases	and	2737	controls	would	be	required.	Hence,	EMR	databases	are	typically	large	
enough	that	methods	such	as	cross	validation	and	bootstrapping	are	not	necessary.	
• Modelling	choices	will	first	be	informed	by	the	form	of	the	outcome.	Given	a	continuous	
outcome,	linear	regression	is	often	used.	Given	a	binary	outcome,	logistic	regression	is	
often	used.	Given	time-to-event	data,	Cox	regression	is	often	used.	These	initial	
methods	can	be	used	to	explore	the	relationships	between	the	predictors	and	the	
outcome;	more	advanced	methods,	such	as	generalized	additive	models,	may	be	used	
where	appropriate.	For	example,	non-linearity	is	better	captured	by	using	generalized	
additive	models	[42],	which	is	possible	without	overfitting	due	to	the	large	sample	sizes	
of	EMR	databases	that	support	such	techniques;	this	method	should	be	used	when	
researchers	suspect	the	relationship	between	risk	indicator	and	outcome	is	non-linear	
on	the	log	scale.	Other	non-parametric	methods	exist,	such	as	decision	trees	or	k-
nearest	neighbours,	which	may	fit	the	data	better	or	be	more	in	line	with	researcher	
objectives	(e.g.	decision	trees	are	easily	interpreted,	which	may	be	desired	by	
researchers).	Use	these	alternative	methods	where	appropriate.	
• Assess	the	performance	of	models	produced	by	examining	the	discrimination	and	
calibration	of	models	on	the	development	set.	As	mentioned,	discrimination	can	be	
assessed	visually	using	an	ROC	curve	or	objectively	using	the	c-statistic,	which	is	
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equivalent	to	the	area	under	the	ROC	curve	(AUC)	[8].	Calibration	is	a	measure	of	how	
well	a	model	fits	the	given	data.	One	method	of	assessing	calibration	plots	the	average	
estimated	risk	within	each	risk	decile	against	the	actual	proportion	of	patients	who	
develop	the	disease	within	the	decile	[4].	Ideally,	the	estimated	risk	should	correspond	
to	the	observed	rate	of	disease	within	the	validation	set.	Another	method	of	assessing	
calibration	uses	the	Hosmer-Lemeshow	test	[43];	however,	this	test	is	over-sensitive	
when	applied	to	large	sample	sizes	and	thus	is	not	suitable	for	working	with	EMR	data	
[10].	Based	on	these	criteria,	the	best	model	can	be	selected.	
• Once	the	best	model	is	selected,	rebuild	the	model	using	both	the	training	and	
development	sets	to	make	use	of	all	available	data.	As	recommended	by	TRIPOD	[25],	
evaluate	the	chosen	model	using	the	validation	set	and	report	these	validation	
measures;	this	is	referred	to	as	internal	validation.	Internal	validation	of	a	model	
assesses	the	performance	of	a	model	on	a	held	out	portion	of	the	data.	External	
validation	assesses	the	performance	of	a	model	on	a	similar	but	different	group	of	
patients	that	were	not	used	when	developing	the	model	[44];	external	validation	
requires	the	use	of	an	external	dataset.	At	a	minimum,	a	model	must	be	validated	
internally	by	partitioning	the	dataset	or	using	cross-validation	methods.	However,	
external	validation	is	the	strongest	evidence	that	a	model	is	a	good	predictor	of	disease.	
	
Results	(Case	Study:	An	Osteoarthritis	Risk	Model)	
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In	the	following,	we	present	our	case	study	of	constructing	a	prognostic	predictive	model	for	
the	5-year	risk	of	an	osteoarthritis	diagnosis.	As	the	most	common	joint	disorder	worldwide	
[45],	osteoarthritis	represents	a	growing	concern	for	older	adults	[46].	Our	prognostic	
predictive	model	enables	the	identification	of	patients	at	high	risk	of	developing	osteoarthritis,	
which	in	turn	allows	health	and	lifestyle	modifications	aimed	at	reducing	the	risk	of	disease	
development	to	be	targeted	to	those	with	highest	risk	[47,48].	Ultimately,	we	see	this	model	
being	developed	into	a	purpose-built	tool,	which	can	be	used	routinely	by	primary	care	
practitioners	during	patient	encounters	to:	1)	deliver	a	quantitative	assessment	of	
osteoarthritis	risk	in	patients	where	the	patient	and/or	primary	care	practitioner	is	concerned	
about	osteoarthritis	risk;	and	2)	act	as	a	risk	screening	tool	to	detect	high	risk	patients	who	may	
have	gone	undetected	otherwise.	
	
1.	Scoping	and	Background	Search	
	
We	sought	to	develop	a	prognostic	predictive	model	for	the	diagnosis	of	osteoarthritis	in	
Canadian	primary	care.	We	begin	by	examining	existing	literature	to	identify	established	risk	
indicators	for	the	development	of	osteoarthritis.	These	were:	BMI	(Body	Mass	Index)	[49–55],	
previous	leg	injury	[49,51–53],	leg	length	inequality	[56],	older	age	[50–52,54,55],	female	sex	
[50–52,55],	osteoporosis	[50],	family	history	[55],	occupation	[55],	and	physical	workload	[54].		
	
We	used	the	DELPHI	(Deliver	Primary	Healthcare	Information)	database	to	develop	our	
prognostic	predictive	model.	The	DELPHI	database	contains	de-identified	patient	records	from	
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the	EMRs	of	14	primary	care	practices	throughout	Southwestern	Ontario,	which	includes	more	
than	60,000	patients	[29,57].	Within	this	database	are	all	structured	patient	records,	including:	
patient	encounters,	patient	demographics,	billing	codes,	laboratory	results,	prescriptions,	
referrals,	risk	factor	information,	and	medical	procedures.	The	DELPHI	database	contains	only	
the	structured	data	within	the	EMR;	it	does	not	contain	the	free	text	narrative.	Several	steps	
were	previously	carried	out	from	the	outset	of	database	construction	to	ensure	data	quality,	
including:	EMR	user	support;	implementation	that	did	not	disrupt	the	workflow	of	EMR	users;	
and	data	entry	training	[58].	Ultimately,	we	found	that	DELPHI	contained	data	describing	five	of	
the	nine	risk	indicators	that	we	identified	from	the	literature:	BMI,	previous	leg	injury,	older	
age,	female	sex,	and	osteoporosis.	Data	describing	family	history,	occupation,	leg	length	
inequality,	and	physical	workload	were	not	available.	
	
2.	Data	Preparation	
	
The	DELPHI	network	contributes	data	to	a	Canada-wide	EMR	database	called	CPCSSN	(Canadian	
Primary	Care	Sentinel	Surveillance	Network).	Researchers	working	with	the	CPCSSN	database	
have	constructed	and	validated	a	case	definition	for	osteoarthritis	[59].	Billing	codes,	problem	
list	diagnoses,	laboratory	results,	and	medication	lists	were	used	in	creating	the	case	definition.	
We	used	this	disease	case	definition	in	our	study.	We	created	risk	factor	definitions	for	each	risk	
factor;	information	was	combined	from	multiple	data	elements	to	derive	the	case	definitions,	
as	seen	below.	These	case	definitions	were	constructed	through	examination	of	the	DELPHI	
data	dictionary	and	through	consultation	with	physician	end-users.	
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Table	1:	Risk	factor	definitions	for	DELPHI	database.	
Risk	Factor	 Table	Name	 Value	
Age	 Patient	Demographics	 Numeric	
Sex	 Patient	Demographics	 Male	or	female	
BMI	 Patient	Encounter	 Numeric	
Leg	Injury	 Billing	
Health	Condition	
Encounter	Diagnosis	
	
ICD-9	Codes:	
• 820-29:	fracture	of	lower	limb	
• 843:	sprain	or	strain	of	hip	and	thigh	
• 844:	sprain	or	strain	of	knee	and	leg	
• 928:	crushing	injury	to	lower	limb	
Osteoporosis	 Billing	
Health	Condition	
Encounter	Diagnosis	
ICD-9	Code:	
• 733:	Osteoporosis	and	other	bone	disorders	
Health	Condition	
Encounter	Diagnosis	
Risk	Factor	
“osteoporosis”	
Medications	 Alendronic	acid	
Risedronic	acid	
Ibandronic	acid	
	
The	risk	indicator	“osteoporosis,”	as	we	have	chosen	to	define	it,	includes	any	suspected	bone	
disorder.	This	includes	use	of	the	ICD-9	(International	Classification	of	Diseases	–	Ninth	
Revision)	code	733	(which	is	used	to	note	osteoporosis	and	other	bone	disorders)	in	the	
problem	list,	billing	data,	or	encounter	diagnosis	fields;	the	term	“osteoporosis”;	or	prescription	
of	a	medication	commonly	used	for	the	treatment	or	prevention	of	osteoporosis.	Specific	
diagnoses	of	osteoarthritis	(ICD-9	code	733.0)	were	not	available.	
We	then	examined	the	DELPHI	database	in	regards	to	the	quality	of	its	data.	We	considered	
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data	concordance;	however,	information	was	only	found	in	one	location	for	each	risk	factor.	
Not	all	data	were	plausible:	some	patients	had	a	birth	year	of	0;	we	considered	these	values	to	
be	missing.	We	also	considered	BMI	measurements	greater	than	100	kg/m2	or	less	than	10	
kg/m2	to	be	missing,	as	these	values	were	deemed	implausible.	Risk	indicator	data	for	leg	
length	inequality,	physical	workload,	occupation,	and	family	history	were	completely	missing,	
and	we	were	not	able	to	obtain	them	by	linking	with	external	databases.	Information	pertaining	
to	age	was	missing	in	roughly	15%	of	patients	while	information	pertaining	to	BMI	was	missing	
in	roughly	28%	of	patients.	We	used	multiple	imputation	to	complete	these	data.	
The	DELPHI	database	contains	all	visit	data	for	the	participating	practices	up	to	21	January	
2016;	hence,	we	consider	the	information	to	be	current.	
3.	Cohort	Construction	
	
The	construction	of	our	cohort	is	illustrated	in	Figure	1.	We	included	any	patient	who	had	a	visit	
with	their	primary	care	practitioner	between	1	January	2008	and	31	December	2009	and	had	
not	been	previously	diagnosed	with	osteoarthritis.	Risk	indicators	were	assessed	on	the	date	of	
this	visit	by	examining	records	prior	to	and	including	this	date.	Patients	were	then	“followed”	in	
the	database	for	5	years.	Those	who	were	diagnosed	with	osteoarthritis	within	this	time	period	
and	who	had	at	least	one	recorded	visit	after	the	5-year	period	were	considered	positive	cases	
of	osteoarthritis.	The	additional	recorded	visit	was	required	to	ensure	that	they	were	not	lost	to	
follow-up/censored.	We	also	eliminated	any	patient	who	was	diagnosed	with	osteoarthritis	at	
their	follow-up	visit.	This	was	done	as	we	could	not	be	sure	that	this	diagnosis	would	not	have	
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been	present	prior	to	the	end	of	follow-up	had	they	visited	their	primary	care	practitioner.	Our	
final	dataset	included	28447	patients.	
	
Figure	1:	Flowchart	depicting	patients	included	in	retrospective	cohort.	
	
Having	identified	our	cohort,	we	then	developed	and	applied	our	risk	indicator	definitions.	We	
began	by	determining	a	BMI	value	for	each	patient.	Because	many	patients	did	not	have	a	
measurement	recorded	at	intake,	we	used	interpolation	of	adjacent	values	to	estimate	BMI	at	
intake.	Where	there	was	only	a	measurement	on	one	side	of	the	intake	visit	(either	before	or	
after,	not	both)	we	used	the	closest	value.		
Table	2:	Characteristics	of	our	research	sample	
Characteristics	
Research	
Sample	
Sample	size	 28447	
Age,	mean	(SD),	years	 42.7	(21.8)	
Females,	%	 55.2%	
BMI,	mean	(SD),	kg/m2	 28.1	(7.9)	
Patients	with	leg	injuries,	%	 4.2%	
Patients	with	osteoporosis,	%	 2.1%	
SD,	Standard	Deviation;	BMI,	Body	Mass	Index	
	
We	then	performed	multiple	imputation	using	our	resulting	cohort.	In	order	to	produce	the	
best	imputation	possible,	we	included	all	identified	risk	indicators	as	well	as	systolic	blood	
pressure,	and	number	of	chronic	diseases;	systolic	blood	pressure	and	number	of	chronic	
diseases	were	included	to	improve	the	imputation,	but	were	not	included	in	the	predictive	
model	as	they	are	not	risk	indicators	for	osteoarthritis.	We	imputed	20	datasets	using	the	MICE	
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package	in	R	[60].		
4.	Model	Building	and	Evaluation	
We	began	by	randomly	partitioning	our	cohort	of	patients	into	training,	development,	and	
validation	sets.	We	then	built	several	predictive	models:		
• Logistic	regression	
• Logistic	regression	with	continuous	predictors	logarithmically	transformed	
• Logistic	regression	with	the	addition	of	quadratic	transformations	of	the	continuous	
predictors	
• Generalized	additive	models	
• Generalized	additive	models	with	continuous	predictors	logarithmically	transformed	
Each	model	was	built	from	each	of	the	20	imputed	training	datasets	separately,	then	combined	
using	Rubin’s	rules	[61].	We	used	both	logistic	regression	(using	the	R	package:	stats	[62])	and	
generalized	additive	models	(using	the	R	package:	mgcv	[63]).	We	also	applied	logarithmic	
transformations	to	the	positive-valued	continuous	variables:	age	and	BMI.	To	evaluate	each	
combined	model,	we	applied	them	to	the	development	sets,	resulting	in	20	measures	of	
performance,	which	were	also	combined,	again	using	Rubin’s	rules.		
After	comparing	the	performance	of	the	different	models	on	the	development	set,	we	found	
that	the	simplest	model	–	logistic	regression	–	appeared	to	be	the	best.	Having	selected	this	
model,	we	re-estimated	the	parameters	using	both	the	training	and	development	set,	which	
produced	our	final	model.	The	performance	of	our	final	model	was	then	assessed	using	the	
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same	performance	measures	on	the	reserved	validation	set.	
The	following	model	was	produced:	
Logit	=	-5.29	+	0.04	(Age)	+	0.14	(Sex)	+	0.02	(BMI)	+	0.36	(Leg	Injury)	+	0.60	(Osteoporosis)	
Discrimination:	The	area	under	the	ROC	curve	showed	the	model	had	a	good	discriminative	
ability	(AUC	0.74,	95%	confidence	interval:	0.71	to	0.76).	
Calibration:	Model	calibration	is	illustrated	in	Figure	2.	Calibration	appears	good	for	low-risk	
patients.	The	model	tends	to	overestimate	risk	in	the	upper	deciles,	then	underestimates	risk	at	
large	values	in	the	extreme	upper	deciles.	
Figure	2:	Calibration	plot	of	logistic	regression	model’s	performance	on	test	set.	
	
Discussion	
Prognostic	predictive	models	serve	several	purposes	in	the	clinical	setting:	screening	of	
individuals	to	identify	high	risk	patients;	prediction	of	future	morbidity;	and	assistance	in	
primary	care	practitioners’	clinical	decision	making	[10].	However,	the	construction	of	a	
prognostic	predictive	model	is	no	simple	task;	there	is	no	single	method	of	developing	these	
models.	Our	framework,	FRAMR-EMR,	aims	to	provide	guidance	for	researchers	aspiring	to	
construct	such	models	using	EMR	data.		
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Construction	of	a	prognostic	predictive	model	following	FRAMR-EMR	yielded	a	predictive	model	
capable	of	estimating	5-year	risk	of	osteoarthritis	diagnosis.	Internal	validation	of	the	model’s	
performance	demonstrated	good	discrimination	and	moderate	calibration.	Compared	to	
previous	osteoarthritis	risk	estimation	models	[16,64,65],	our	model	is	more	easily	applied	in	
clinical	practice	as	it	requires	no	additional	measurements	by	the	physician	beyond	what	is	
already	stored	within	the	EMR;	previous	models	require	information	such	as	occupational	
status	or	a	Kellgren	and	Lawrence	(K&L)	score	based	on	radiographic	images.	By	exclusively	
using	predictors	that	are	already	contained	within	the	EMR,	our	tool	will	be	able	to	operate	in	
the	background	of	the	EMR,	flagging	patients	during	a	patient	encounter	that	are	at	high	risk	of	
developing	osteoarthritis.	By	identifying	these	patients	at	high-risk	of	osteoarthritis,	this	simple	
tool	will	allow	physicians	to	be	aware	of	which	patients	should	be	closely	monitored	for	disease	
development	and	for	whom	strategies	to	reduce	risk,	such	as	weight	loss	[66],	should	be	
prescribed.	We	foresee	this	model	aiding	in	the	decision	making	process	of	physicians	to	help	
delay	or	prevent	the	development	of	osteoarthritis	in	high-risk	individuals.	
	
Existing	methods	of	predictive	model	development	typically	assume	that	the	data	to	be	used	
for	predictive	model	development	are	in	a	readily	usable	form	[8,10,11];	this	is	consistently	not	
true	for	EMR	data	[23]	as	they	are	created	for	clinical,	not	research	use	[67].	Our	work	aims	to	
address	this	by	discussing	ways	in	which	data	may	be	less	than	ideal	and	providing	methods	of	
handling	and	cleaning	such	data.	Missing	data,	for	example,	is	an	issue	of	particular	significance	
in	EMRs;	we	have	suggested	methods	for	dealing	with	missing	data.	We	also	address	how	to	
construct	a	cohort	for	the	development	of	predictive	models,	since	the	cohort	must	be	defined	
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and	constructed	from	the	EMR	data	alone.	Similar	work,	such	as	that	of	Ferrão	et	al.,	has	
presented	general	guidelines	for	preprocessing	patient	record	data	to	convert	it	into	a	useable	
form	for	research;	in	contrast,	our	work	presents	a	comprehensive	framework	specifically	for	
developing	a	prognostic	predictive	model	using	primary	care	EMR	data.	The	FRAMR-EMR	
describes	all	the	steps	necessary	to	move	from	raw	patient	data	to	a	functioning	predictive	
model.	
	
The	use	of	EMR	data	for	prognostic	predictive	modelling	has	many	advantages	over	other	data	
sources,	including	the	size	and	amount	of	detail	contained	within	these	databases;	however,	
there	exist	many	limitations	that	must	be	considered	as	well.	Our	framework	has	been	
developed	specifically	for	the	use	of	EMR	data	alone;	we	did	not	explicitly	consider	other	data	
sources	except	through	linkage.	EMR	data	often	do	not	contain	information	regarding	
potentially	highly	predictive	risk	indicators,	such	as	lifestyle	factors,	which	are	not	regularly	
recorded	in	an	EMR.	For	example,	physical	workload	has	been	shown	to	be	highly	associated	
with	development	of	osteoarthritis	[54];	however,	information	regarding	physical	workload	was	
not	contained	within		the	DELPHI	database.		
	
Conclusions	
	
Our	goal	was	to	produce	a	useful	framework	for	researchers	and	analysts	interested	in	
developing	prognostic	predictive	models	based	on	EMR	data,	and	to	illustrate	its	use	on	a	
specific,	real-world	predictive	modelling	problem.	Our	hope	is	that	the	increased	production	of	
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high	quality	prognostic	predictive	models	will	enable	communication	of	accurately	estimated	
risks	of	developing	future	disease,	and	in	turn	will	help	to	tailor	interventions	to	individual	
patients’	risk	profiles	and	reduce	the	overall	burden	of	disease.	
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